Simulations Plus Inc

Simulations Plus Inc Stock Forecast & Price Prediction

Live Simulations Plus Inc Stock (SLP) Price
$33.79

1

Ratings

  • Buy 1
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$33.79

P/E Ratio

76.79

Volume Traded Today

$189,525

Dividend

$0.06

52 Week High/low

51.22/32.69

Simulations Plus Inc Market Cap

$732.5M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $SLP ๐Ÿ›‘

Before you buy SLP you'll want to see this list of ten stocks that have huge potential. Want to see if SLP made the cut? Enter your email below

SLP Summary

From what 1 stock analysts predict, the share price for Simulations Plus Inc (SLP) might increase by 68.69% in the next year. This is based on a 12-month average estimation for SLP. Price targets go from $47 to $65. The majority of stock analysts believe SLP is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

SLP Analyst Ratings

About 1 Wall Street analysts have assigned SLP 1 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Simulations Plus Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on SLP. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

SLP stock forecast by analyst

These are the latest 20 analyst ratings of SLP.

Analyst/Firm

Rating

Price Target

Change

Date

Scott Schoenhaus
Keybanc

Overweight

$47

Initiates

Jul 29, 2024
Constantine Davides
JMP Securities

Market Perform


Initiates

Jul 16, 2024
Matt Hewitt
Craig-Hallum

Buy

$56

Reiterates

Jul 3, 2024
Max Smock
William Blair

Outperform


Initiates

Jun 28, 2024
Francois Brisebois
Oppenheimer

Outperform

$65

Maintains

Jun 13, 2024
Matt Hewitt
Craig-Hallum

Buy

$56

Maintains

Jun 13, 2024
Matt Hewitt
Craig-Hallum

Buy

$51

Maintains

Jan 4, 2024
Francois Brisebois
Oppenheimer

Outperform

$67

Reiterates

Jul 7, 2023

Oppenheimer

Outperform


Maintains

Jun 21, 2023
David Larsen
BTIG

Buy

$55

Initiates

May 9, 2023
Francois Brisebois
Oppenheimer

Outperform

$65

Reiterates

Apr 6, 2023
Dane Leone
Raymond James

Outperform

$70

Maintains

Aug 29, 2022
Matt Hewitt
Craig-Hallum

Buy

$60

Maintains

Jul 7, 2022
Matt Hewitt
Craig-Hallum

Buy

$53

Upgrade

Oct 26, 2021
Dane Leone
Raymond James

Outperform

$54

Maintains

Jul 13, 2021

Craig-Hallum

Hold


Downgrade

Jan 12, 2021

Raymond James

Outperform


Initiates

Oct 16, 2020

Oppenheimer

Outperform


Initiates

Sep 8, 2020

Craig-Hallum

Buy


Initiates

Jan 6, 2020

Sidoti & Co.



Initiates

Mar 12, 2013

SLP Company Information

  • Company Name: Simulations Plus, Inc.
  • Industry: Drug discovery and development software
  • Business Model: Operates through two segments: Software and Services
  • Key Products:
    • GastroPlus: Simulates absorption and drug interactions in humans and animals
    • DDDPlus and MembranePlus: Simulation products for drug development
    • DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, MITOsym: Mechanistic and mathematical modeling products
    • ADMET Predictor: Predicts molecular properties based on structures
    • MedChem Designer: Aids in drug design
    • MonolixSuite: For population analyses and clinical trial data
  • Consulting Services:
    • Clinical pharmacology-based services
    • Population pharmacokinetic and pharmacodynamic modeling
    • Exposure-response analyses and clinical trial simulations
    • Data programming and technical writing for regulatory submissions
    • Early drug discovery services
    • Quantitative systems pharmacology/toxicology modeling support
  • Target Customers: Pharmaceutical, biotechnology, agrochemical, cosmetics, food industry companies, academic and regulatory agencies
  • Founded: 1996
  • Headquarters: Lancaster, California
SLP
Simulations Plus Inc (SLP)

When did it IPO

N/A

Staff Count

192

Country

United States

Sector/Industry

Healthcare/Health Information Services

CEO

Market Cap

$732.5M

Simulations Plus Inc (SLP) Financial Data

In 2023, SLP generated $59.6M in revenue, which was a increase of 10.52% from the previous year. This can be seen as a signal that SLP's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$41.6M

Revenue From 2021

$46.5M

11.73 %
From Previous Year

Revenue From 2022

$53.9M

16.01 %
From Previous Year

Revenue From 2023

$59.6M

10.52 %
From Previous Year
  • Revenue TTM $67.0M
  • Operating Margin TTM 10.1%
  • Gross profit TTM $47.9M
  • Return on assets TTM 3.6%
  • Return on equity TTM 5.5%
  • Profit Margin 14.4%
  • Book Value Per Share 9.04%
  • Market capitalisation $732.5M
  • Revenue for 2021 $46.5M
  • Revenue for 2022 $53.9M
  • Revenue for 2023 $59.6M
  • EPS this year (TTM) $0.47

Simulations Plus Inc (SLP) Latest News

No news data available.

...

SLP Frequently asked questions

The highest forecasted price for SLP is $65 from Francois Brisebois at Oppenheimer.

The lowest forecasted price for SLP is $47 from Scott Schoenhaus from Keybanc

The SLP analyst ratings consensus are 1 buy ratings, 0 hold ratings, and 0 sell ratings.